Eric Jonasch, MD, discusses the evolution of treatment options for patients with renal cell carcinoma (RCC) that he has witnessed during his career. From the first RCC patients that he treated with cytokine therapies, to the revolution of tyrosine kinase inhibitors and immunotherapy combinations, Dr Jonasch believes that we are now at the point in this evolution where there is potential that a subset of patients can be cured, something he could not have believed at the start of his journey.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: The Evolution of Treatment Options in Renal Cell Carcinoma - Medscape - Jan 28, 2022.
Comments